Agenus Inc. (AGEN) is an immunotherapy company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on AGEN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Agenus could be a solid choice for investors.
Current Quarter Estimates for AGEN
In the past 30 days, earnings estimates have narrowed from a loss of 22 cents a share 30 days ago, to a loss of 19 today, a move of 13.6%.
Current Year Estimates for AGEN
Meanwhile, Agenus’ current year figures are also looking quite promising, with the consensus estimate seeing a boost for this time frame, narrowing from a loss of 97 cents per share 30 days ago to a loss of 86 cents per share today, an increase of 11.3%.
Bottom Line
The stock has also started to move higher lately, adding 6.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment